We use cookies for a better user experience. Read our Privacy Policy

I Agree

Severe Acute Respiratory Syndrome Treatment Market

Severe Acute Respiratory Syndrome Treatment Market (Drug Class: Antibiotics, Antivirals, Corticosteroids, Monoclonal Antibodies, and Others; and Indication: SARS-CoV and SARS-CoV-2) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Severe Acute Respiratory Syndrome Treatment Market Outlook 2031

  • The industry was valued at US$ 24.6 Bn in 2021
  • It is projected to record a CAGR of -14.5% from 2022 to 2031 and reach US$ 8.6 Bn by the end of 2031

Analysts’ Viewpoint

Emergence of the novel coronavirus (SARS-CoV-2) led to a global pandemic, which resulted in high demand for SARS treatment and vaccine development. Significant investment by governments in the development of SARS treatments and vaccines is driving the global severe acute respiratory syndrome treatment market.

Rise in prevalence of SARS is expected to augment the demand for effective treatments, thus creating lucrative opportunities for key market players. Furthermore, lack of FDA-approved treatments for SARS disease and high unmet medical needs associated with the disease are creating opportunities for players to develop new and innovative treatments.

Decline in number of COVID-19 cases, decrease in research & development funding, rise in distribution & access challenges, and shift in focus toward other health concerns are projected to restrain the market in the next few years.

Severe Acute Respiratory Syndrome Treatment Market

Severe Acute Respiratory Syndrome Treatment Market Introduction

Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused by the SARS coronavirus. There is no specific treatment for SARS; however, treatment typically involves supportive care to relieve symptoms and help the body fight the virus. This could include oxygen therapy, pain & fever management, and breathing support.

SARS treatment primarily includes medications, medical devices, and inpatient care services. Increase in incidence of SARS and rise in demand for effective treatments and supportive care are projected to bolster global severe acute respiratory syndrome market size.

However, the global outbreak of COVID-19 caused by a related coronavirus has overshadowed the market for SARS treatment. The COVID-19 pandemic led to significant investment in research & development of treatments and vaccines for the disease, as well as surge in demand for medical supplies and services related to the treatment of COVID-19.

Government and Private Sector Funding for R&D and Production of SARS Treatments

Governments and private organizations across the world provided support for research & development and production of treatments for SARS. The World Health Organization (WHO) played a significant role in coordinating international efforts to control the spread of SARS and support research on its treatment. In 2003, the WHO established a global research network to accelerate the development of treatments and vaccines for SARS.

Private organizations, such as pharmaceutical companies, were also involved in the development of treatments for SARS. For instance, Gilead Sciences developed the antiviral drug remdesivir, which has been shown to be effective in reducing the time to recovery in patients with SARS-CoV-2 (COVID-19).

Governments have also provided funding for SARS research through grants and public-private partnerships. For instance, the U.S. National Institutes of Health (NIH) provided funding for several studies aimed at understanding SARS and developing treatments, and has supported the development of vaccines and antiviral medications.

Overall, support from government and private organizations has been critical in advancing the understanding of SARS and developing treatments to control its spread and improve patient outcomes.

Increase in Strategic Initiatives by Key Players

Partnerships and collaborations among pharmaceutical companies, research institutions, and government agencies have played an important role in advancing the development and availability of SARS treatments. Partnerships between pharmaceutical companies and research institutions have led to the development of new antiviral drugs and vaccine candidates for SARS.

Government agencies have collaborated with pharmaceutical companies to support the clinical development of SARS treatments and ensure rapid approval and distribution. These partnerships have accelerated the development of effective treatments for SARS and improved patient outcomes.

Adoption of Antibiotics in Secondary Bacterial Infection in COVID-19 Patients

In terms of drug class, the antibiotics segment held the largest global severe acute respiratory syndrome treatment market share in 2021. Demand for antibiotics for the treatment of SARS caused by SARS-CoV-2 has been limited during the COVID-19 pandemic, as antibiotics are not effective against viruses.

Supportive care and antiviral drugs, such as remdesivir and favipiravir, are the primary treatments for SARS-CoV-2. However, antibiotics could be recommended in some COVID-19 cases, where a secondary bacterial infection occurs.

Rise in Focus on Development of Treatments for SARS-CoV-2

Based on indication, the SARS-CoV-2 segment dominated the global severe acute respiratory syndrome treatment market in 2021. SARS-CoV-2 is a virus that causes COVID-19, a respiratory illness that has become a global pandemic. The COVID-19 pandemic has led to an increase in demand for treatments and vaccines to prevent and treat the disease.

Pharmaceutical companies and research institutions are focusing on developing treatments for SARS-CoV-2, including antiviral drugs, monoclonal antibodies, and vaccines.

Provision of Appropriate Medications and Dosages in Hospital Pharmacies

In terms of distribution channel, the hospital pharmacies segment is expected to account for significant share of the global severe acute respiratory syndrome market during the forecast period. Majority of patients with SARS require hospitalization and treatment with antiviral medications, which are administered through intravenous (IV) infusion in a hospital setting.

Hospital pharmacies play a critical role in ensuring that patients receive appropriate medications, dosages, and administration methods. They also collaborate with healthcare providers to monitor patients' progress and adjust treatment plans as required.

Hospital pharmacies have access to a range of medications, including specialized therapeutics for lung diseases. These pharmacies are staffed with trained pharmacists who can provide expert advice on medication use and management. They also work closely with other healthcare professionals, such as doctors and nurses, which allows for better coordination of care and improved patient outcomes.

Regional Outlook of Global Severe Acute Respiratory Syndrome Treatment Market

As per SARS treatment market report, North America dominated the global severe acute respiratory syndrome market in 2021. This can be ascribed to the increase in research & development efforts toward development of vaccines & antiviral medications to prevent SARS and measures to contain its spread. Management of SARS is primarily supportive, and includes measures such as providing oxygen, managing fever & other symptoms, and preventing secondary infections.

The market in North America is expected to be driven by the rise in research & development of new treatments and vaccines. However, it is likely to be influenced by the ongoing COVID-19 pandemic and availability of effective treatments and vaccines for both SARS and COVID-19.

Analysis of Key Players

Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by prominent manufacturers in the global severe acute respiratory syndrome treatment market. Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, Merck, GSK, Gilead Sciences, Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., CN Bio, AbbVie, and Swedish Orphan Biovitrum are the leading market players.

Key Developments in Global Severe Acute Respiratory Syndrome Treatment Market

  • In December 2022, Pfizer, Inc. and Clear Creek Bio, Inc. declared a research alliance and exclusive license agreement for the development of potential SARS-CoV-2 papain-like protease (PLpro) inhibitors for the oral treatment of COVID-19. PLpro is a necessary enzyme that, along with the main protease (Mpro), is essential for viral replication.
  • In March 2022, Scripps Research and AbbVie announced a global collaboration to develop novel, direct-acting antiviral treatments for COVID-19
  • In November 2021, the Infection Innovation Consortium (iiCON), a global collaborative infectious disease research & development program, and CN Bio announced a research collaboration to validate the next generation of COVID-19 research tools

The severe acute respiratory syndrome treatment market report profiles key players based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

Global Severe Acute Respiratory Syndrome Treatment Market Snapshot

Attribute

Detail

Size in 2021

US$ 24.6 Bn

Forecast (Value) in 2031

More than US$ 8.6 Bn

Growth Rate (CAGR)

-14.5%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • Antibiotics
    • Antivirals
    • Corticosteroids
    • Monoclonal Antibodies
    • Others
  • Indication
    • SARS-COV
    • SARS-COV-2
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • AstraZeneca plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GSK
  • Merck
  • Pfizer
  • Regeneron Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum
  • CN Bio
  • AbbVie

Customization Scope

Available upon request

Pricing

Available upon request

Severe Acute Respiratory Syndrome Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global severe acute respiratory syndrome treatment market in 2021?

The global industry was valued at US$ 24.6 Bn in 2021.

How big will it be in 2031?

It is projected to reach US$ 8.6 Bn by 2031.

What will be the CAGR during the forecast period?

The CAGR is anticipated to be -14.5% from 2022 to 2031.

Which are the prominent trends that affect growth?

Increase in SARS-CoV-2 (COVID-19) cases globally and support from government & private organizations for R&D and production of SARS treatments.

Which region will account for major share?

North America is projected to account for significant share during the forecast period.

Who are the prominent players in the business?

Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, Merck, GSK, Gilead Sciences, Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., CN Bio, AbbVie, and Swedish Orphan Biovitrum.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global C Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Regulatory Scenario

    5.3. Insights on Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective

    5.4. COVID-19 Impact Analysis

6. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. Antibiotics

        6.3.2. Antivirals

        6.3.3. Corticosteroids

        6.3.4. Monoclonal Antibodies

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Indication, 2017–2031

        7.3.1. SARS-CoV

        7.3.2. SARS-CoV-2

    7.4. Market Attractiveness Analysis, by Indication

8. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region, 2017–2031

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2031

        10.2.1. Antibiotics

        10.2.2. Antivirals

        10.2.3. Corticosteroids

        10.2.4. Monoclonal Antibodies

        10.2.5. Others

    10.3. Market Value Forecast, by Indication, 2017–2031

        10.3.1. SARS-CoV

        10.3.2. SARS-CoV-2

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Indication

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2031

        11.2.1. Antibiotics

        11.2.2. Antivirals

        11.2.3. Corticosteroids

        11.2.4. Monoclonal Antibodies

        11.2.5. Others

    11.3. Market Value Forecast, by Indication, 2017–2031

        11.3.1. SARS-CoV

        11.3.2. SARS-CoV-2

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Indication

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2031

        12.2.1. Antibiotics

        12.2.2. Antivirals

        12.2.3. Corticosteroids

        12.2.4. Monoclonal Antibodies

        12.2.5. Others

    12.3. Market Value Forecast, by Indication, 2017–2031

        12.3.1. SARS-CoV

        12.3.2. SARS-CoV-2

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Indication

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2031

        13.2.1. Antibiotics

        13.2.2. Antivirals

        13.2.3. Corticosteroids

        13.2.4. Monoclonal Antibodies

        13.2.5. Others

    13.3. Market Value Forecast, by Indication, 2017–2031

        13.3.1. SARS-CoV

        13.3.2. SARS-CoV-2

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Indication

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2031

        14.2.1. Antibiotics

        14.2.2. Antivirals

        14.2.3. Corticosteroids

        14.2.4. Monoclonal Antibodies

        14.2.5. Others

    14.3. Market Value Forecast, by Indication, 2017–2031

        14.3.1. SARS-CoV

        14.3.2. SARS-CoV-2

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Indication

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company (2021)

    15.3. Company Profiles

        15.3.1. Regeneron Pharmaceuticals, Inc.

            15.3.1.1. Company Overview

            15.3.1.2. Drug Class Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. Merck

            15.3.2.1. Company Overview

            15.3.2.2. Drug Class Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. GSK

            15.3.3.1. Company Overview

            15.3.3.2. Drug Class Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. Gilead Sciences, Inc.

            15.3.4.1. Company Overview

            15.3.4.2. Drug Class Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. AstraZeneca plc

            15.3.5.1. Company Overview

            15.3.5.2. Drug Class Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. F. Hoffman La Roche

            15.3.6.1. Company Overview

            15.3.6.2. Drug Class Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. Pfizer

            15.3.7.1. Company Overview

            15.3.7.2. Drug Class Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. Eli Lilly and Company

            15.3.8.1. Company Overview

            15.3.8.2. Drug Class Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Swedish Orphan Biovitrum

            15.3.9.1. Company Overview

            15.3.9.2. Drug Class Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

        15.3.10. CN Bio

            15.3.10.1. Company Overview

            15.3.10.2. Drug Class Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Financial Overview

            15.3.10.5. Strategic Overview

        15.3.11. AbbVie

            15.3.11.1. Company Overview

            15.3.11.2. Drug Class Portfolio

            15.3.11.3. SWOT Analysis

            15.3.11.4. Financial Overview

            15.3.11.5. Strategic Overview

List of Tables

Table 01: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 03: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 08: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 16: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 20: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 24: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2017 and 2031

Figure 02: Global Severe Acute Respiratory Syndrome Treatment Market Revenue (US$ Mn), by Drug Class, 2021

Figure 03: Global Severe Acute Respiratory Syndrome Treatment Market Value Share, by Drug Class, 2021

Figure 04: Global Severe Acute Respiratory Syndrome Treatment Market Revenue (US$ Mn), by Indication, 2021

Figure 05: Global Severe Acute Respiratory Syndrome Treatment Market Value Share, by Indication, 2021

Figure 06: Global Severe Acute Respiratory Syndrome Treatment Market Revenue (US$ Mn), by Distribution Channel, 2021

Figure 07: Global Severe Acute Respiratory Syndrome Treatment Market Value Share, by Distribution Channel, 2021

Figure 08: Global Severe Acute Respiratory Syndrome Treatment Market Value Share, by Region, 2021

Figure 09: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Global Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031

Figure 11: Global Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031

Figure 12: Global Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031

Figure 13: Global Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022-2031

Figure 14: Global Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 15: Global Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031

Figure 16: Global Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Region, 2017 and 2031

Figure 17: Global Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Region, 2022-2031

Figure 18: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country, 2017–2031

Figure 20: North America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country, 2017 and 2031

Figure 21: North America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031

Figure 22: North America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031

Figure 23: North America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 24: North America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 25: North America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031

Figure 26:North America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 27: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 29: Europe Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 30: Europe Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031

Figure 31: Europe Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031

Figure 32: Europe Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 33: Europe Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 34: Europe Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031

Figure 35: Europe Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 36: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 38: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 39: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031

Figure 40: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031

Figure 41: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 42: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 43: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031

Figure 44: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 45: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 47: Latin America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 48: Latin America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031

Figure 49: Latin America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031

Figure 50: Latin America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 51: Latin America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 52: Latin America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031

Figure 53: Latin America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 54: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 56: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 57: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031

Figure 58: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031

Figure 59: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 60: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 61: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031

Figure 62: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

434

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved